This fully remote, multisite, double-blind, placebo-controlled, randomized superiority trial investigated the efficacy of a 10-week home-based tDCS treatment for MDD. 174 participants (120 women, 54 men) were randomized to active (n=87) or sham (n=87) treatment. Active tDCS (2 mA) showed significantly greater improvement in depressive symptoms (HDRS) than sham (0 mA) (95% CI = 0.51-4.01, P=0.012). The 10-week home-based tDCS treatment demonstrated high efficacy, acceptability, and safety.
Publisher
Nature Medicine
Published On
Oct 21, 2024
Authors
Rachel D. Woodham, Sudhakar Selvaraj, Nahed Lajmi, Harriet Hobday, Gabrielle Sheehan, Ali-Reza Ghazi-Noori, Peter J. Lagerberg, Maheen Rizvi, Sarah S. Kwon, Paulette Orhii, David Maislin, Lucia Hernandez, Rodrigo Machado-Vieira, Jair C. Soares, Allan H. Young, Cynthia H. Y. Fu
Tags
tDCS
Major Depressive Disorder
randomized trial
home-based treatment
efficacy
placebo-controlled
Related Publications
Explore these studies to deepen your understanding of the subject.
